ANI Pharmaceuticals, Inc.
ANIP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $614,376 | $486,816 | $316,385 | $216,136 |
| % Growth | 26.2% | 53.9% | 46.4% | – |
| Cost of Goods Sold | $250,210 | $181,513 | $138,785 | $100,610 |
| Gross Profit | $364,166 | $305,303 | $177,600 | $115,526 |
| % Margin | 59.3% | 62.7% | 56.1% | 53.5% |
| R&D Expenses | $44,581 | $34,286 | $22,318 | $11,369 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $249,636 | $161,697 | $124,044 | $84,294 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $69,365 | $62,349 | $66,521 | $59,656 |
| Operating Expenses | $363,582 | $258,332 | $212,883 | $155,319 |
| Operating Income | $584 | $46,971 | -$35,283 | -$39,793 |
| % Margin | 0.1% | 9.6% | -11.2% | -18.4% |
| Other Income/Exp. Net | -$22,796 | -$27,099 | -$27,382 | -$16,265 |
| Pre-Tax Income | -$22,212 | $19,872 | -$62,665 | -$56,058 |
| Tax Expense | -$3,690 | $1,093 | -$14,769 | -$13,455 |
| Net Income | -$18,522 | $18,779 | -$47,896 | -$42,603 |
| % Margin | -3% | 3.9% | -15.1% | -19.7% |
| EPS | -1.04 | 0.95 | -3.05 | -3.4 |
| % Growth | -209.5% | 131.1% | 10.3% | – |
| EPS Diluted | -1.04 | 0.94 | -3.05 | -3.4 |
| Weighted Avg Shares Out | 19,318 | 18,001 | 16,260 | 12,596 |
| Weighted Avg Shares Out Dil | 19,318 | 18,194 | 16,260 | 12,596 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $17,602 | $26,940 | $28,052 | $11,922 |
| Depreciation & Amortization | $67,731 | $59,791 | $59,653 | $47,252 |
| EBITDA | $63,121 | $106,603 | $25,040 | $3,116 |
| % Margin | 10.3% | 21.9% | 7.9% | 1.4% |